A dedicated team of researchers and scientists from Israel’s Ben-Gurion University has made a remarkable leap forward. Our groundbreaking technology redefines the approach to managing chronic inflammation. For the first time, we can directly target inflamed tissues, restoring balance by precisely adjusting pH levels.
The innovation lies in our use of amorphous minerals, which identify inflammation sites in the body, acting like guided missiles and utilizing their hybrid function only within the inflamed area: They efficiently balance the pH level, enhancing the body’s absorption of the minerals, which leads to rapid tissue restoration. This innovation is backed by 130 patents. It represents not just a step forward, but a leap in our understanding and approach to inflammation management.
The blue crayfish, a notable inhabitant of freshwater environments and measuring an impressive 30 centimeters (11.811 inches), exhibits a regenerative capacity unmatched by any other creature on the planet.
Despite its habitat’s low mineral content, the crayfish can regenerate its extensive exoskeleton, tissues, muscles, and other cells within 3 days, while others take at least one month. The key factor in this rapid renewal process is its inherent ability to convert natural minerals into amorphous minerals, defying the crystalline norm.
The breakthrough didn’t just end with a revelation from the blue crayfish. Our team replicated this natural process, leading to the synthesis and stabilization of amorphous minerals in a vegan way – without using the actual creatures. This venture resulted in a substance tailored to target inflammatory sites in the gastrointestinal tract, effectively adjusting pH levels and delivering essential minerals to support the body’s reparative processes. When encountering imbalanced pH levels, the carbonate ions quickly convert into bicarbonate, the body’s natural regulator, thus providing the essential augmentation needed for physiological balance. This advancement laid the groundwork for developing tailored approaches to managing conditions like Crohn’s and colitis.
PH Gastrilex is the embodiment of this natural mimicry, crafted to transport its active ingredients safely through the stomach, releasing them only upon reaching the inflamed intestinal areas. The delivery method patented by Amorphical ensures that the active ingredients are optimally utilized in the body, offering a new level of support for conditions like Crohn’s disease and other inflammatory bowel disorders.
A Deeper Dive As we venture deeper into the scientific narrative, the pivotal role of Amorphous Calcium Carbonate (ACC) comes to light. ACC is not introduced as a mere substance but as a culmination of extensive research into immune-modulating therapies. ACC’s potential lies in its ability to buffer against acidosis—a condition frequently associated with inflammatory processes in the body. This buffering capacity is crucial for maintaining cellular functions and integrity, especially in the inflamed tissues of IBD patients.
For an in-depth perspective on our scientific advancements, review the extensive array of studies and publications.
Israel serves as a living laboratory, demonstrating the life-changing improvements PH Gastrilex can bring to those with chronic inflammation. Tens of thousands of people are using Amorphical products daily to eliminate chronic inflammation, osteoporosis, Crohn’s and colitis. Their experiences substantiate the product’s unique ability to enhance quality of life without the long-term risks associated with conventional medications.
An unparalleled profile In clinical settings, ACC has demonstrated a remarkable safety profile, even at higher dosages, without significant adverse events, especially when compared to traditional therapies for IBD. This profile presents ACC as a significant advancement in therapeutic options, where the balance between efficacy and safety is paramount.
inflammation global care offers a comprehensive approach to IBD care with PH Gastrilex. Leveraging the expertise of clinical nutritionists and the extensive experience of dietitian Adi Zusman, we provide a dynamic support program for those with Crohn’s and colitis. Our scientifically backed PH Gastrilex, endorsed by the Israeli Ministry of Health, enhances the quality of life for those facing chronic inflammation, showcasing our commitment to innovative and effective health solutions.
We are on the cusp of a transformative chapter in the management of chronic inflammation. Approved by the Israeli Ministry of Health (MOH) and progressing through phase 2 with the FDA and EMA, our technology is on the path to becoming an officially sanctioned medicine in Europe and the USA—anticipated within the next 2 to 3 years. We encourage the medical community to consider this not merely as an alternative but as a significant evolution in patient treatment and care.
At IGC, we recognize the uniqueness of everyone’s journey. Below are our recommended approaches for incorporating our product into your daily regimen. We encourage you to select the path that aligns with your personal wellness needs and goals, while also considering our dosage recommendations.
If you notice improvements after these initial 3 weeks with Gastrilex, continue with 6 capsules daily for another 2 weeks before reducing the dosage to 4 capsules daily.
Should there be no noticeable improvement after consistently taking 6 capsules daily for 2 weeks, increase the dosage to 8 capsules daily. Once you observe improvements for at least 2 consecutive weeks, you can reduce
the dosage to 6 capsules daily for one week and then further down to 4 capsules for maintenance.
After about one and a half months, once improvements are stable, maintain a dose of 4 capsules daily for ongoing support.First Month: For addressing active inflammation, begin with 8 capsules daily. Distribute the dosage as follows: 3 capsules in the morning, 2 in the afternoon, and 3 in the evening.
Second Month: After observing symptom relief, reduce the intake to 6 capsules daily. Continue this dosage for the entire month to consolidate the improvements.
Subsequent Period: Transition to a maintenance dose of 4 capsules per day for ongoing support.
Maintain an interval of one hour between consuming PH Gastrilex capsules and eating food or taking other medications/substances. This helps ensure optimal absorption and effectiveness of the capsules.
Some individuals may initially experience gas and discomfort due to the interaction of the active ingredients with the inflamed gastrointestinal area. This is more likely with Approach B, given the higher starting dose, but can also occur with Approach A. Such symptoms generally diminish within three weeks. If discomfort or pain persists beyond this period, please consult with a healthcare professional.
The product is a nutritional solution and does not require a prescription. Pregnant and nursing women, individuals taking prescription medication, and children should consult with a physician before use.
We extend an invitation to the medical community to discover the potential of PH Gastrilex. For a more comprehensive discussion on its clinical applications and to understand how Israel has become a pivotal proof of concept for this innovative approach, please contact our Medical Affairs team.
If you are a new customer, your satisfaction and positive results are our top priority.
This is why we recommend starting with three packages for your initial trial. Typically, you can expect to notice improvements within 3 to 4 weeks of regular use.
Should the product not meet your expectations or fail to deliver results, we offer a money-back guarantee on each unopened package